Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has secured an immediately available local supply of MDMA, the final component that allows patient dosing to commence for its MDMA-assisted therapy trial to treat post-traumatic stress disorder (PTSD). The locally available MDMA will be supplied to Emyria through a collaboration with Mind Medicine Australia (MMA) and the Australian National University (ANU). This supply ensures the company can commence its ethics-approved MDMA-assisted therapy (MDMA-AT) trial while it awaits Health Canada to approve a comprehensive MDMA shipment from Canada.
Emyria set to begin MDMA study after securing local supply
